EFFECTS OF NOVEL THERAPIES ON HEART FAILURE PATIENTS INVESTIGATE THE EFFICACY AND SAFETY OF EMERGING TREATMENTS OR THERAPIES FOR HEART FAILURE MANAGEMENT
Main Article Content
Keywords
Heart failure, Novel therapies, Emerging treatments, Personalized medicine.
Abstract
Background: Heart failure (HF) is a serious worldwide health issue that is defined by the heart's incapacity to adequately pump blood to meet the body's needs
Objective: The research main objective was to examine the safety and effectiveness of novel medications or treatments for the management of HF.
Methodology: The purpose of this prospective cohort study was to assess the safety and effectiveness of new heart failure treatments at MTI Lady Reading Hospital Peshawar, Pakistan. A total of 320 adult patients with heart failure (HFpEF or HFrEF) were enrolled between 1st April 2020 and 26th March 2023. Comprehensive data was collected using structured data collecting forms, and treatment outcomes were assessed using follow-up examinations conducted at 3, 6, and 12 months. Subgroup studies based on HF subtype were planned, and descriptive and inferential statistical analyses were used to compare results between innovative and traditional therapy.
Results: The groups' baseline characteristics were comparable. The mean ejection fraction increased by +8.4% (±3.6) in the Novel Therapy group (NTG) and +5.9% (±2.8) in the Standard Therapy group (STG) (p < 0.001). Furthermore, improvement in NYHA functional class was observed in a larger proportion of patients in the NTG (76.2% vs. 62.5%, p = 0.013). According to the Kansas City Cardiomyopathy Questionnaire, the group receiving novel therapy had a considerably higher quality of life (45.7 ± 6.3) than the group receiving standard therapy (39.5 ± 7.1) (p < 0.001). The group receiving Novel Therapy saw fewer hospitalizations (15.6%) for worsening heart failure than the group receiving Standard Therapy (23.8%) (p = 0.049). There was no discernible difference in mortality rates across the groups (6.3% vs. 9.4%, p = 0.214).
Conclusion: Comparing novel therapy to established treatments, there were notable improvements in heart function, symptom management, and quality of life. These results highlight the necessity for ongoing research and individualized treatment plans, and they promote the inclusion of novel therapies in HF care protocols.
References
2. Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. Journal of clinical medicine. 2016 Jun 29;5(7):62.
3. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. European Journal of Cardiovascular Nursing. 2005 Sep;4(3):198-206.
4. Sapna FN, Raveena FN, Chandio M, Bai K, Sayyar M, Varrassi G, Khatri M, Kumar S, Mohamad T. Advancements in heart failure management: a comprehensive narrative review of emerging therapies. Cureus. 2023 Oct 4;15(10).
5. Drapkina OM, Yafarova AA, Kaburova AN, Kiselev AR. Targeting gut microbiota as a novel strategy for prevention and treatment of hypertension, atrial fibrillation and heart failure: current knowledge and future perspectives. Biomedicines. 2022 Aug 19;10(8):2019.
6. Devadoss R, Dhillon G, Sharma P, Verma RK, Munjal R, Kashyap R. Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment. Journal of Cardiovascular Development and Disease. 2024 Jan 5;11(1):15.
7. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circulation research. 2008 Jun 20;102(12):1458-70.
8. Gabisonia K, Recchia FA. Gene therapy for heart failure: new perspectives. Current heart failure reports. 2018 Dec;15:340-9.
9. Doppler SA, Deutsch MA, Lange R, Krane M. Cardiac regeneration: current therapies—future concepts. Journal of thoracic disease. 2013 Oct;5(5):683.
10. Angel BG, Saltzman H, Kusmirek LS. Device management in heart failure. Current Cardiology Reports. 2017 Nov;19:1-1.
11. Forsyth P, Beezer J, Bateman J. Holistic approach to drug therapy in a patient with heart failure. Heart. 2023 Aug 1;109(15):1183-91.
12. Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, Brunetti ND. New targets in heart failure drug therapy. Frontiers in Cardiovascular Medicine. 2021 May 5;8:665797.
13. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008 Sep 16;118(12):1294-303.
14. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European heart journal. 2014 Oct 21;35(40):2797-815.
15. Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, Lee HY, Kim KH, Yoo BS, Kang SM, Baek SH. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. Journal of the American Heart Association. 2019 Mar 19;8(6):e011077.
16. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation. 2016 Jun 7;133(23):2254-62.
17. DeVore AD, Hammill BG, Sharma PP, Qualls LG, Mentz RJ, Waltman Johnson K, Fonarow GC, Curtis LH, Hernandez AF. In‐hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. Journal of the American Heart Association. 2014 Jul 11;3(4):e001088.
18. Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European heart journal. 2021 Jan 7;42(2):178-88.
19. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101–Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. Journal of clinical oncology. 2017 Mar 10;35(8):870-7.
20. Mullens W, Dauw J, Gustafsson F, Mebazaa A, Steffel J, Witte KK, Delgado V, Linde C, Vernooy K, Anker SD, Chioncel O. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2024 Jan 25.
21. Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, Lee HY, Kim KH, Yoo BS, Kang SM, Baek SH. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. Journal of the American Heart Association. 2019 Mar 19;8(6):e011077.
22. Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, Laufs U, Tschöpe C, Anker SD, Lam CS, Voors AA. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology. 2020 Sep;109:1079-98.
23. Kolben Y, Kessler A, Puris G, Nachman D, Alvarez P, Briasoulis A, Asleh R. Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly. Reviews in Cardiovascular Medicine. 2022 Jan 14;23(1):16.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Muhammad Younas Ali
Demonstrator Anatomy, Gajju Khan Medical College / Bacha Khan Medical Complex, Swabi
Dr Obaid Ullah
General Medicine, Trust Doctor, Sunderland Royal Hospital, STSFT
Dr Irsa Sikandar
House Officer Medicine, Lady Reading Hospital, Peshawar
Dr Muhammad Amin Noor
Medical Officer, General/Internal Medicine, Naseer Teaching Hospital, Peshawar
Dr Faizan Ahmad
Training Medical Officer, Emergency Medicine, Lady Reading Hospital, Peshawar
Dr Aima Yousaf
Clinical Fellow Medicine, George Eliot Hospital, Nuneaton
Dr Ayiz Jan
Trainee Medical Officer, Internal Medicine MTI Lady Reading Hospital, Peshawar
Dr Mah Rukh
Trainee Medical Officer, Internal Medicine, MTI Khyber Teaching Hospital, Peshawar
Dr Adeel Khan
Trainee Medical Officer, Internal Medicine, Lady Reading Hospital, peshawar